0 05/06/2023 30/06/2024 2024-06-30 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2023-06-05 Sage Accounts Production 24.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 14914160 2023-06-05 2024-06-30 14914160 2024-06-30 14914160 2023-06-04 14914160 bus:RegisteredOffice 2023-06-05 2024-06-30 14914160 bus:LeadAgentIfApplicable 2023-06-05 2024-06-30 14914160 bus:Director1 2023-06-05 2024-06-30 14914160 bus:Director2 2023-06-05 2024-06-30 14914160 core:WithinOneYear 2024-06-30 14914160 core:ShareCapital 2024-06-30 14914160 core:RetainedEarningsAccumulatedLosses 2024-06-30 14914160 bus:SmallEntities 2023-06-05 2024-06-30 14914160 bus:AuditExemptWithAccountantsReport 2023-06-05 2024-06-30 14914160 bus:SmallCompaniesRegimeForAccounts 2023-06-05 2024-06-30 14914160 bus:PrivateLimitedCompanyLtd 2023-06-05 2024-06-30 14914160 bus:FullAccounts 2023-06-05 2024-06-30
Company registration number: 14914160
Gamma Medical Limited
Unaudited filleted financial statements
30 June 2024
Gamma Medical Limited
Contents
Directors and other information
Accountants report
Statement of financial position
Notes to the financial statements
Gamma Medical Limited
Directors and other information
Directors L A Roberts (Appointed 5 June 2023)
R M Wollan (Appointed 5 June 2023)
Company number 14914160
Registered office Parkgates, Bury New Road
Prestwich
Manchester
M25 0JW
Accountants Alexander Bursk Ltd
Parkgates, Bury New Road
Prestwich
Manchester
M25 0JW
Bankers Wise Payments Ltd
6th Floor
The Tea Building
56 Shoreditch High Street
London
E1 6JJ
Gamma Medical Limited
Accountants' report to the board of directors on the preparation of the
unaudited statutory financial statements of Gamma Medical Limited
Period ended 30 June 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Gamma Medical Limited for the period ended 30 June 2024 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com /en/members/regulations-standards-and-guidance/.
This report is made solely to the board of directors of Gamma Medical Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Gamma Medical Limited and state those matters that we have agreed to state to the board of directors of Gamma Medical Limited as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Gamma Medical Limited and its board of directors as a body for our work or for this report.
It is your duty to ensure that Gamma Medical Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Gamma Medical Limited. You consider that Gamma Medical Limited is exempt from the statutory audit requirement for the period.
We have not been instructed to carry out an audit or a review of the financial statements of Gamma Medical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Alexander Bursk Ltd
Accountants
Parkgates, Bury New Road
Prestwich
Manchester
M25 0JW
21 February 2025
Gamma Medical Limited
Statement of financial position
30 June 2024
30/06/24
Note £ £
Current assets
Stocks 5,521
Cash at bank and in hand 1,158
_______
6,679
Creditors: amounts falling due
within one year 4 ( 12,334)
_______
Net current liabilities ( 5,655)
_______
Total assets less current liabilities ( 5,655)
_______
Net liabilities ( 5,655)
_______
Capital and reserves
Called up share capital 100
Profit and loss account ( 5,755)
_______
Shareholders deficit ( 5,655)
_______
For the period ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 21 February 2025 , and are signed on behalf of the board by:
L A Roberts
Director
Company registration number: 14914160
Gamma Medical Limited
Notes to the financial statements
Period ended 30 June 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Parkgates, Bury New Road, Prestwich, Manchester, M25 0JW.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Creditors: amounts falling due within one year
30/06/24
£
Other creditors 12,334
_______
5. Related party transactions
During the period the company entered into the following transactions with related parties:
Transaction value Balance owed by /(owed to)
Period Period
ended ended
30/06/24 30/06/24
£ £
Soma Surgical Limited - ( 6,000)
Arthromed Limited - ( 5,000)
_______ _______
R M Wollan is a director of Soma Surgical Limited and L A Roberts is a director of Arthromed Limited.
6. Controlling party
The company is controlled jointly by L A Roberts and R M Wollan.